MedPath

¡®Faecal microbiota transfusion for decolonization ofmultidrug resistant Enterobacteriaceae in renaltransplant recipients (RESET): a pilot study.¡¯

Conditions
multi drug resistance colonizationrenal transplant recipientsMDR infectionsfaecal microbiota transfusion
Registration Number
NL-OMON22882
Lead Sponsor
Department of Infectious Diseases and Medical Microbiology, Leiden University Medical Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
12
Inclusion Criteria

In order to be eligible to participate in this study, a subject must meet all of the following
criteria:

Exclusion Criteria

A potential subject who meets any of the following criteria will be excluded from
participation in this study:

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Frequency and magnitude of any adverse events within 1 month of faecal microbiota<br>transfusion, including infections. The occurrence of renal transplant related adverse events<br>(graft loss, biopsy-proven acute rejection, doubling of serum creatinine) within 3 months after<br>FMT.
Secondary Outcome Measures
NameTimeMethod
Secondary / exploratory study parameters:<br /><br>- Number of participants with intestinal carriage of MDRE after FMT (assessed at 1 and 2<br>weeks and 1, 3 and 6 months after FMT).<br /><br>- Number of participants with one or more MDRE infection(s) within 6 months after FMT.<br /><br>- Change (relative to baseline) in the microbiota composition during 6 months of follow-up.<br /><br>- Change in microbiome diversity, calculated by Shannon diversity index, during 6 months of<br>follow-up.<br /><br>- Prevalence of antibiotic resistance genes in faecal samples during 6 months of follow up as<br>determined by metagenomics.<br /><br>- Magnitude of intra-patient variability in immunosuppressive drug exposure.
© Copyright 2025. All Rights Reserved by MedPath